Quanterix Corp (NASDAQ:QTRX) Director Martin D. Madaus sold 1,600 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $25.25, for a total value of $40,400.00. Following the completion of the sale, the director now owns 8,149 shares in the company, valued at approximately $205,762.25. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Shares of Quanterix stock traded up $0.05 during midday trading on Friday, hitting $24.96. The company had a trading volume of 707 shares, compared to its average volume of 99,419. The company has a debt-to-equity ratio of 0.06, a quick ratio of 7.00 and a current ratio of 7.61. The stock has a market capitalization of $704.29 million, a P/E ratio of -17.46 and a beta of 1.36. The company has a 50 day moving average of $23.27 and a 200 day moving average of $26.37. Quanterix Corp has a 52-week low of $17.08 and a 52-week high of $36.15.
Quanterix (NASDAQ:QTRX) last posted its quarterly earnings results on Friday, November 8th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.01. The company had revenue of $14.94 million for the quarter, compared to the consensus estimate of $12.52 million. Quanterix had a negative return on equity of 54.74% and a negative net margin of 75.78%. Equities research analysts forecast that Quanterix Corp will post -1.52 EPS for the current year.
Several research firms recently weighed in on QTRX. Canaccord Genuity restated a “buy” rating and issued a $35.00 price target on shares of Quanterix in a research note on Thursday, November 7th. Zacks Investment Research upgraded Quanterix from a “sell” rating to a “hold” rating in a research note on Tuesday, November 26th.
Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Simoa HD-1 instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids.
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.